HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer

ESMO Open. 2019 Jul 8;4(3):e000530. doi: 10.1136/esmoopen-2019-000530. eCollection 2019.

Yoshiaki Nakamura^{1

2}, Kentaro Sawada¹, Satoshi Fujii³, Takayuki Yoshino¹

¹ Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
² Translational Research Support Section, Translational Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
³ Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

No abstract available

Keywords: HER2; anti-EGFR therapy; circulating tumor DNA; metastatic colorectal cancer.